title: Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated.
abstract: Bevacizumab is largely used in colorectal cancer patients. Postsurgical healing complications have been described for patients following treatment with Bevacizumab. We report three cases of spontaneous intestinal perforation following infusion of Bevacizumab. From January 2002 through October 2010, Bevacizumab was delivered in 143 patients. Spontaneous intestinal perforation occurred in 3 cases (2.1 %). Bevacizumab may result in severe complications. Therefore, it is important to consider every patient treated with Bevacizumab at risk for life-threatening gastro-intestinal complications.
authors.affiliation: Department of General Surgery, Campus Bio-Medico University of Rome, Rome, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Borzomati
authors.forename: Gennaro
authors.initials: G
authors.lastname: Nappo
authors.forename: Sergio
authors.initials: S
authors.lastname: Valeri
authors.forename: Bruno
authors.initials: B
authors.lastname: Vincenzi
authors.forename: Valter
authors.initials: V
authors.lastname: Ripetti
authors.forename: Roberto
authors.initials: R
authors.lastname: Coppola
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007416:Intestinal Perforation / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab